Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone.

Metabolism: clinical and experimental - 1 Jan 1999

Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y

Abstract excerpt

Troglitazone is a new oral hypoglycemic agent that reduces insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM). However, this agent increases serum lipoprotein(a) [Lp(a)], which is known as an atherogenic lipoprotein. The relationships between the response of Lp(a) to troglitazone and the apolipoprotein(a) [apo(a)] phenotype were investigated in this study. Nineteen NIDDM patients were treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Apolipoproteins
Share to Apoprotein(a)

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Lipoprotein(a)

Share to Phenotype

Share to Protein Isoforms

Share to Thiazoles

Source

Identifiers

PMID: 9920136
DOI: 10.1016/s0026-0495(99)90001-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone.PMID 9920136Read ↗

Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.Semantic proximity Read ↗

Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.Semantic proximity Read ↗

Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia.Semantic proximity Read ↗

Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia.Semantic proximity Read ↗

Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus.Semantic proximity Read ↗

Relation of apolipoprotein (a) phenotypes to diabetic retinopathy in elderly type 2 diabetes.Semantic proximity Read ↗

Thiazolidinediones, dyslipidaemia and insulin resistance syndrome.Semantic proximity Read ↗

Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.Semantic proximity Read ↗

Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype.Semantic proximity Read ↗

Effect of ageing on plasma lipoprotein(a) levelsSemantic proximity Read ↗

Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.Semantic proximity Read ↗

The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.